Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2023 | Phase I trial of INA03 in patients with R/R acute leukemia: preliminary results

Sylvain Garciaz, MD, Paoli-Calmettes Institute, Marseille, France, briefly discusses the preliminary results from a Phase I trial evaluating the safety and efficacy of INA03, an anti-CD71 antibody-drug conjugate (ADC), in patients with relapsed/refractory (R/R) acute leukemias (AL; NCT03957915). This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.